MT 218
Alternative Names: MT-218; ZD2-N3-Gd(HP-DO3A)Latest Information Update: 09 Aug 2024
At a glance
- Originator Molecular Theranostics
- Class Diagnostic conjugates; Gadolinium-containing contrast agents; Peptide diagnostics
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
- Phase I Solid tumours
Most Recent Events
- 25 Jul 2024 Phase-I/II clinical trials in Prostate cancer (Diagnosis) in USA (IV) (NCT06262139)
- 15 Feb 2024 Molecular Theranostics plans a phase I/II trial for Prostate cancer (Diagnosis) in USA (IV) in March 2024 (NCT06262139)
- 08 Dec 2023 Pharmacodnamics, pharmacokinetic and adverse events data from preclinical studies in Solid tumors released by Molecular Theranostics